A randomized trial of rosuvastatin in the prevention of venous thromboembolism

New England Journal of Medicine

Volumn 360, Issue 18, 2009, Pages 1851-1861

  Glynn, Robert J ^a   Danielson, Eleanor ^a   Fonseca, Francisco A H ^b   Genest, Jacques ^c   Gotto Jr , Antonio M ^d   Kastelein, John J P ^e   Koenig, Wolfgang ^f   Libby, Peter ^a   Lorenzatti, Alberto J ^g   MacFadyen, Jean G ^a   Nordestgaard, Børge G ^h   Shepherd, James ⁱ   Willerson, James T ^j   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF ULM   (Germany)

^g HOSPITAL PRIVADO   (Argentina)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j ST LUKE S EPISCOPAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; VENOUS THROMBOEMBOLISM; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; RISK; VEIN THROMBOSIS;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PULMONARY EMBOLISM; PYRIMIDINES; RISK; SULFONAMIDES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 65449138698     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0900241     Document Type: Article

References (36)

1. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348:1435-1441 (Pubitemid 36407172)
2. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773-1779 (Pubitemid 350137491)
3. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-645 (Pubitemid 27097428)
4. Hansson P-O, Eriksson H, Welin L, Svärdsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "The Study of Men Born in 1913." Arch Intern Med 1999;159:1886-1890.
5. Tsai AW, Cushman M, Rosamond W, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-1189 (Pubitemid 34522408)
6. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005;162:975-982 (Pubitemid 41619468)
7. Ageno W, Beccattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102. (Pubitemid 350301144)
8. Lowe GDO. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it? J Thromb Haemost 2006;4:1882-1885
9. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006;4:1886-1890
10. Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007;147:525-533
11. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005;25:287-294
12. Kaba NK, Francis CW, Moss AJ, et al. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004;2:718-725 (Pubitemid 40185709)
13. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70. (Pubitemid 32606333)
14. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000;132:689-696 (Pubitemid 30244167)
15. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161:1405-1410 (Pubitemid 32681161)
16. Doggen CJM, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004;2:700-701 (Pubitemid 40185706)
17. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004;18:477-482 (Pubitemid 39215361)
18. Ramcharan AS, van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJM. HMG-CoA-reductase inhibitors, other lipid lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009;7:514-520
19. Sørensen HT, Horvath-Puho E, Søgaard KK, et al. Arterial cardiovascular events, statins, low dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009;7:521-528
20. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 2002;53:101-105 (Pubitemid 34117746)
21. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2008;67:99-109.
22. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006;59:819-828 (Pubitemid 44040877)
23. Ray JG. Do we care if statins prevent venous thromboembolism? J Thromb Haemost 2004;2:695-696
24. Ridker PM, Fonseca FAH, Genest J, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007;100:1659-1664 (Pubitemid 350122337)
25. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
26. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-1495
27. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation 2005;112:2735-2752
28. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593 (Pubitemid 28144815)
29. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 2000;83:657-660 (Pubitemid 30248509)
30. Everett BM, Glynn RJ, Buring JE, Ridker PM. Lipid biomarkers, hormone therapy, and risk of venous thromboembolism in women. J Thromb Haemost 2009 January 24 (Epub ahead of print).
31. Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008;112:2675-2680
32. Eichinger S, Pecheniuk NM, Hron G, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007;115:1609-1614 (Pubitemid 46648646)
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979 [Erratum, N Engl J Med 1997;337:356.] (Pubitemid 27152782)
34. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002;113:636-642 (Pubitemid 36015799)
35. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005;112:720-726 (Pubitemid 41099052)
36. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Goldhaber SZ. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005;93:76-79 (Pubitemid 40124258)